Research Topics
| Arnold FreedmanSummaryAffiliation: Harvard University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Follicular lymphoma: 2011 update on diagnosis and managementArnold Freedman
Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA 02115, USA
Am J Hematol 86:768-75. 2011..Stem cell transplantation (SCT) including both autologous and allogeneic SCT or experimental agent therapy is considered for recurrent disease...
Effective purging of autologous hematopoietic stem cells using anti-B-cell monoclonal antibody-coated high-density microparticles prior to high-dose therapy for patients with non-Hodgkin's lymphomaIain J Webb
Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Biol Blood Marrow Transplant 8:429-34. 2002..5 days (range, 8-17 days). This nonmagnetic negative-depletion technology is simple, rapid, and effective in depleting target cells to undetectable levels, with excellent recovery of nontarget cells...- Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphomaArnold Freedman
Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 27:3036-43. 2009..To evaluate patient-specific immunotherapy with mitumprotimut-T (idiotype keyhole limpet hemocyanin [Id-KLH]) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in CD20(+) follicular lymphoma... - Non-transplant-related treatment options in follicular lymphomaArnold S Freedman
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
Biol Blood Marrow Transplant 12:53-8. 2006 - Follicular lymphoma: 2012 update on diagnosis and managementArnold Freedman
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
Am J Hematol 87:988-95. 2012..Autologous stem cell transplantation (SCT) has not shown a survival benefit in first remission patients. SCT including both autologous and allogeneic SCT or experimental agent therapy is considered for recurrent disease... - Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapyAbba C Zubair
Connell O'Reilly Cell Manipulation Core Facility, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
Transfusion 44:253-61. 2004 - B-cell purging in autologous stem-cell transplantation for non-Hodgkin lymphomaEric Jacobsen
Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 02115, USA
Lancet Oncol 5:711-7. 2004..We analysed data on the purging of B cells by use of antibodies in the setting of autologous transplantation, with emphasis on the emerging technique of in vivo purging... - An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphomaEric Jacobsen
Harvard Medical School, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
Curr Opin Oncol 16:106-13. 2004.... - Follicular lymphoma with bilateral testicular and epididymal involvement: case report and review of the literatureEric Jacobsen
Department of Medical Oncology, Dana-Farber Cancer Institute, Havard Medical School, Boston, 02115, USA
Leuk Lymphoma 46:1663-6. 2005..He is now 6 months into therapy and responding well. A review of the literature demonstrated this to be the first confirmed case of testicular and epididymal involvement with grade I follicular lymphoma... - Early neutrophil engraftment following autologous BMT provides a functional predictor of long-term hematopoietic reconstitutionAbba Zubair
Connell O'Reilly Cell Manipulation Core Facility and the Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
Transfusion 43:614-21. 2003..CONCLUSION: TNE is an in vivo functional measure of LHR and is a more sensitive predictor of LHR at 1 year after BMT than either CD34+ cell dose or CFU-GM infused... - Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantationEdwin P Alyea
Biol Blood Marrow Transplant 8:601-7. 2002..However, these adverse events do not lead to inferior probability of relapse-free survival because they are accompanied by a reduction in relapse rates... 
Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcomePhilippe Armand
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Biol Blood Marrow Transplant 14:418-25. 2008..These results emphasize the importance of lymphoma histology for patients undergoing RIC SCT, as well as the lack of relevance of donor chimerism for outcome in this patient population...- Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remissionJennifer R Brown
Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
Biol Blood Marrow Transplant 13:1057-65. 2007..99-8.8, P=.0002). No significant predictors of overall survival were identified. These results at 12-year follow-up suggest that a subset of follicular lymphoma patients can experience prolonged survival with ABMT in first remission... - Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-upAma Z S Rohatiner
Cancer Research UK Medical Oncology Unit, St Bartholomew s Hospital, London, United Kingdom
J Clin Oncol 25:2554-9. 2007.... - Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphomaJonathan W Friedberg
James P Wilmot Cancer Center, University of Rochester, 601 Elmwood Avenue, Box 704, Room 1 4118C, NY 14642, USA
Curr Treat Options Oncol 7:276-84. 2006..Until such trials are mature, we do not recommend using these agents in combination outside of the research setting... - Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemiaJohn G Gribben
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
Blood 106:4389-96. 2005..From these findings we have altered our approach for patients with high-risk CLL and are currently exploring the role of related and unrelated allogeneic SCT following reduced-intensity conditioning regimens... - Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphomaJennifer R Brown
Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
J Clin Oncol 23:2208-14. 2005..Although the incidence of MDS/AML starts to plateau, the incidence of solid tumors continues to rise. Second malignancies are responsible for a significant fraction of overall mortality following ABMT... - Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicityJonathan W Friedberg
James P Wilmot Cancer Center, University of Rochester, Rochester, NY 14642, USA
Blood 105:489-95. 2005..CpG treatment resulted in no significant toxicity, providing rationale for further testing of this exciting combination immunotherapy approach to NHL... - Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphomaJonathan W Friedberg
Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Br J Haematol 117:828-34. 2002..Further studies of this rational combination are warranted and ongoing... - Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphomaJennifer R Brown
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
Leuk Lymphoma 45:315-20. 2004..003). Outcomes of autologous BMT in patients with disseminated marginal zone NHL are similar to those in follicular NHL, and suggest that certain patients may experience prolonged disease-free survival... - Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphomaAnn S LaCasce
Dana Farber Cancer Institute, Boston, MA 02115 6084, USA
Semin Hematol 45:85-9. 2008..Until such trials are mature, we do not recommend using these agents in combination outside of the research setting... - CXCL13 (BCA-1) is produced by follicular lymphoma cells: role in the accumulation of malignant B cellsHerve Husson
Department of Medicine, Harvard Medical School, Boston, MA, USA
Br J Haematol 119:492-5. 2002..The production of CXCL13 by FL cells and CXCL12 by stromal cells probably directs and participates in the accumulation of FL cells within specific anatomic sites... - Multicolour fluorescence in situ hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcomeValia S Lestou
Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver, BC, Canada
Br J Haematol 122:745-59. 2003.... - Hodgkin disease associated with T-cell non-Hodgkin lymphomas: case reports and review of the literatureJennifer R Brown
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
Am J Clin Pathol 121:701-8. 2004..These observations imply that, similar to the observations in B-cell NHLs occurring with HD, a subset of synchronous and metachronous T-cell NHLs and HD may be related clonally... - Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arraysHerve Husson
Department of Medicine, Harvard Medical School, Boston, MA, USA
Blood 99:282-9. 2002..These findings provide a basis for future studies into the pathogenesis and pathophysiology of FL and may lead to the identification of potential therapeutic targets as well as antigens for immunotherapeutic strategies...
Research Grants
- INTEGRIN SIGNALING IN ACUTE LYMPHOBLASTIC LEUKEMIAArnold Freedman; Fiscal Year: 2001..Understanding the cell-cell interaction between BM stromal cells and pre-B ALL cells may provide future therapeutic strategies with which to modulate the growth of these leukemias. ..
- Etanercept Therapy in Follicular LymphomaArnold Freedman; Fiscal Year: 2003..This study is a novel approach to treating FL, where targeting the microenvironment of the tumor may inhibit the growth and survival of the neoplastic cells. ..
- CpG Plus Rituximab Therapy in Follicular LymphomaArnold Freedman; Fiscal Year: 2005..This study is a novel approach to treating FL, where augmenting antigen presentation and effector cells may lead to enhanced cytotoxic effects of rituximab and induce anti-tumor immunity. ..